Showing results (21-30 of 86) with videos related to

Sort By:
Pageof 9
Journal of Cardiovascular Pharmacology|November 25, 2011
No evidence of QT prolongation with supratherapeutic doses of aleglitazarStefan Sturm, Darren Bentley, Paul Jordan, et al.
Health Promotion International|July 2, 2025
How Tay adolescent girls and their female carers navigate sexual and reproductive health informationLia Burns, Hannah Pitt, Doan To Thuy Mai, et al.
Expert Opinion on Investigational Drugs|December 1, 2010
Aleglitazar, a balanced PPARα/γ agonist, has no clinically relevant pharmacokinetic interaction with high-dose atorvastatin or rosuvastatinAdam J Foley-Comer, Anne-Marie Young, Fiona Russell-Yarde, et al.
The Lancet Regional Health. Western Pacific|January 31, 2022
SARS-CoV-2 infections and public health responses in schools and early childhood education and care centres in Victoria, Australia: An observational studyKathleen Ryan, Kathryn Snow, Margie Danchin, et al.
International Journal of Environmental Research and Public Health|August 12, 2022
Potential Determinants of Cardio-Metabolic Risk among Aboriginal and Torres Strait Islander Children and Adolescents: A Systematic ReviewChristopher D McKay, Eamon O'Bryan, Lina Gubhaju, et al.
Pageof 9